| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-108
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-15 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2002-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2005-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2005532031-A |
| titleOfInvention |
Polynucleotide constructs and pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anti-cancer treatment |
| abstract |
Novel nucleic acid constructs are provided for downregulating angiogenesis in a tissue of interest. The nucleic acid construct comprises (a) a first polynucleotide region encoding a chimeric polypeptide comprising a ligand binding domain fused to the effector domain of an apoptosis signaling molecule, and (b) a chimeric polypeptide in a particular tissue or cell. And a second polynucleotide region encoding a cis-acting regulatory element to drive expression of In this case, the ligand binding domain is selected to be able to bind to a ligand present in a particular tissue or cell, while binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule Be Also provided is a method of using this nucleic acid construct to treat a disease characterized by excessive or abnormal angiogenesis or cell proliferation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006120924-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006314214-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010525805-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021500355-A |
| priorityDate |
2001-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |